← IPO Calendar

Sai Parenteral's IPO IPO

Mainline24 Mar 202627 Mar 2026
Open
24 Mar 2026
Close
27 Mar 2026
3
Allotment
Listing
Thu, Apr 2, 2026
Price Band
₹372 to ₹392
Issue Size
1,04,28,288 shares (agg. up to ₹409 Cr)
Lot Size
38 Shares
Listing Date
Thu, Apr 2, 2026
Latest GMP
₹0
Est. Gain
0%
✦ AI Insight

GMP Trend

02-04-20260Est. ₹392+0%
01-04-20260Est. ₹392+0%
31-03-20260Est. ₹392+0%

Live Subscription

CategorySubscription (times)
Total1.08x

Restated Financials (₹ Cr.)

Period Ended30 Sep 202531 Mar 202531 Mar 202431 Mar 2023
Assets376.24272.39268.10133.96
Total Income89.43163.74155.1897.03
Profit After Tax7.7614.438.424.38
EBITDA16.2439.4431.7017.64
NET Worth209.3795.7876.4031.49
Reserves and Surplus188.8480.3661.3024.34
Total Borrowing76.0793.95118.7968.55
Amount in ₹ Crore

Peer Comparison

CompanyIssue TypeIssue SizeIssue PricePE RatioListing Day CloseListing Gain/Loss %LTP
Corona Remedies Ltd.Mainboard₹655.37 Cr₹106243.47₹1,438.40+35.44%₹2,064.90 (+0.13%)
Rubicon Research Ltd.Mainboard₹1,377.50 Cr₹48555.75₹628.20+29.53%₹1,419.00 (-3.11%)
Amanta Healthcare Ltd.Mainboard₹126.00 Cr₹12634.59₹141.75+12.50%₹165.27 (-1.98%)
Anlon Healthcare Ltd.Mainboard₹121.03 Cr₹9117.67₹91.73+0.80%₹15.18 (+0.53%)
Speciality Medicines Ltd.SME₹29.14 Cr₹1249.27₹125.90+1.53%₹178.60 (+0.17%)
Accretion Nutraveda Ltd.SME₹24.77 Cr₹12926.27₹191.20+48.22%₹262.00 (-0.70%)
KRM Ayurveda Ltd.SME₹77.49 Cr₹13517.32₹180.70+33.85%₹242.70 (-0.98%)
Curis Lifesciences Ltd.SME₹27.52 Cr₹12812.44₹141.00+10.16%₹105.05 (+2.79%)
Aptus Pharma Ltd.SME₹13.02 Cr₹7011.29₹84.84+21.20%₹249.35 (+2.66%)
Asston Pharmaceuticals Ltd.SME₹27.56 Cr₹12317.83₹124.95+1.59%₹73.50 (-2.00%)
Influx Healthtech Ltd.SME₹58.57 Cr₹9613.04₹126.20+31.46%₹290.00 (-0.60%)
Astonea Labs Ltd.SME₹37.67 Cr₹13527.36₹135.65+0.48%₹283.00 (-1.57%)
Accretion Pharmaceuticals Ltd.SME₹29.75 Cr₹10121.29₹82.95-17.87%₹166.00 (+3.33%)

Objects of the Issue

#Issue ObjectsEst Amt (₹ Cr.)
1Capacity expansion and upgradation of manufacturing facilities110.80
2Establishment of a new R&D Centre;18.02
3Repayment / prepayment of certain outstanding borrowings14.30
4Working capital requirements33.00
5Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and35.64
6General corporate purposes44.74
7Issue Expenses40.84
Total297.34

About Sai Parenteral's IPO

Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing. The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets. The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments. Sai Parenteral's serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa. The company owns and operates five manufacturing facilities in India. Four are lo

Contact Details

Sai Parenteral's Ltd. AddressPlot No 395th floor, Lavanya Arcade Jayabheri EnclaveGachibowli, K.V.Rangareddy, Seri LingampallyHyderabad, Telangana, 500032+91 79979 91301cs@saiparenterals.comVisit Website